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Prognostic factors are essential for patient management andcounseling. Most cancer patients receive treatment based
on the presence or absence of several risk factors. The most
prominent example of this is tumor, node, metastasis staging,
but many diseases are moving beyond the simple one-size-
fits-all stage classification and using stylized prognostic fac-
tors. A notable difficulty in the development of prognostic
factors in today’s clinical research environment is the lack of
implemented guidelines and accepted practices. As a result, it
is not clear what constitutes a prognostic factor. This article
reviews some of this practice, identifies the various biases
that arise from it, and points to solutions, many of which are
discussed in detail at other forums but have been somewhat
ignored, to this point, in the thymoma literature.
The clinical importance of reliable prognostic factors
requires little justification. If one can predict the course of
disease with reasonable precision, treatment choice, fol-
low-up, and patient counseling are greatly enhanced. As a
result, prognostic markers abound in all diseases including
thymoma.1–7 There is no question that our ability to accu-
rately prognosticate has improved by leaps and bounds
during the past 2 decades. Yet, only a handful of markers
have made it into international guidelines for diagnosis,
treatment, or follow-up. This article will discuss some of
the reasons behind the failure of many prognostic markers
to deliver and offer some suggestions to avoid similar
disappointments in the future.
Several examples I will use, and the arguments that will
follow have been made previously elsewhere,8–13 although
not necessarily in the context of thymoma. Some of the
examples in this study are from diagnostic factor studies; this
is because statistical concerns, especially about bias, have
much in common between diagnostic and prognostic factor
studies. Furthermore, diagnostic factor examples often have
the advantage that they are simple and available, and there is
more widespread knowledge about the factor or disease or
both. For the same reason, some of the general references that
discuss methodological issues in biomarker development and
early detection of cancer are also relevant in this study.
ISSUES IN DEFINING PROGNOSTIC FACTORS
Bias in Prognostic Factor Studies
Bias is one of these overused terms that ceased to have
a precise definition. For the purpose of this article, bias refers
to a systematic difference between the sample and the pop-
ulation. If one were to use patients on Medicare to study the
prognosis for papillary thyroid cancer, there would be a
substantial bias as the median age at diagnosis is less than 45
years, yet the sample is, by definition, restricted to those aged
65 years or older. This difference is called systematic in the
sense that it is not because of sampling error. Differences
because of sampling error tend to get smaller as the sample
size increases. Bias, conversely, does not dissipate in larger
samples.
The thyroid cancer example suffers from the malady of
all didactic analogies: it is too obvious and risks overshad-
owing the mechanism for more subtle but still important
biases. Consider a hypothetical example of “New Prognostic
Factor” (NPF), a novel tissue marker that is believed to be
over expressed in certain malignancies. After several in vitro
studies, a retrospective clinical study in thymoma reported on
its potential as a prognostic factor. The investigators found
that the presence of NPF in resected tissue was correlated
with poor survival (p  0.05). This was followed by three
other similar studies from other institutions. All the three
studies were also conducted retrospectively on patients who
underwent surgery. The largest of these three studies (also
larger than the original study) confirmed the significant sur-
vival difference between patients who expressed NPF and
those who did not. The other two studies did not report
statistically significant findings, but they also had smaller
sample sizes. Dismissing these two studies as underpowered
and claiming that the larger study can be taken as a valida-
tion, the investigators of the original study planned a pro-
spective study where NPF was measured first and correlated
with outcome subsequently. They were disappointed to see
that the presence of NPF was not significantly correlated with
survival.
Could this be due to a bias in the original retrospective
study? One can only speculate, but the description of the
patients gives a clue. The retrospective studies were carried
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out from stored tissue. It is entirely possible that the tumors
that were available in the tissue bank were larger than the
typical tumor to have been stored at the first place and then to
have survived the onslaught of the demands on research
specimens from multiple studies. If this is indeed correct, it
would introduce a systematic difference between the sample
(tumors in the tissue bank) and the population (all patients
with thymoma). Because the prospective study mandated
tissue collection on all enrolled patients, it had less (or no)
bias. The difference in conclusion between the original ret-
rospective studies can possibly be due to bias.
Although hypothetical, the scenario has many realistic
elements: most prognostic factors are born out of retrospec-
tive studies, which have findings that are replicated by some,
but not all, other investigations. Most such prognostic factors
fail the more stringent criterion of prospective confirmation.
All retrospective studies are prone to bias—in fact, to multi-
ple sources of bias. Although bias is a problem in prospective
studies as well, its magnitude tends to be smaller, and its
mechanism is better understood.
Types of Bias Common in Prognostic Studies
Selection of Cases
The bias introduced by case selection is perhaps more
appropriately named patient selection or selection bias. This
bias refers to inclusion of patients in such a way that the
resulting sample is extreme (either too good or too bad) in
terms of risk of disease or risk of failure.
An example might help with the concepts. Carcinoem-
bryonic antigen (CEA), by most measures an accepted prog-
nostic marker for patients with colon cancer, attracted wide-
spread clinical attention when it was reported that 35 of 36
patients with colon cancer who were studied had increased
levels of CEA resulting in 97% sensitivity.14 This suggested
some role for CEA as a diagnostic marker. A decade later, the
picture was much less promising, with sensitivities of 5, 25,
45, and 65% reported for stages I, II, III, and IV, respec-
tively.15 This effectively ruled out the use of CEA as a
diagnostic marker. Even among stage IV patients, the differ-
ence between 97 and 65% is simply too big to be attributed
to a single factor. One reason, however, that is likely to
explain this substantial difference is the selection of patients
used in the original study by Thomson et al.14 Although this
original PNAS publication is short on details of who these
patients were, it is likely that they all had very advanced cases
of colon cancer. This is one of the common sources of
selection bias.
Another common source of selection bias is already
exemplified in the previous section. In the discussion of the
availability of tissue for analyzing the NPF, I have already
pointed out the possibility that tumors that were included in
the study were bigger than those that are not included. At a
very basic level, the source of the bias in the CEA and NPF
examples is the same. Yet at another level, they are quite
different. More often than not, proof of principle studies like
the CEA study deliberately choose an extreme sample. Yet,
there was no such intention in the NPF study—the investi-
gators gratefully took whatever was available in the tissue
bank. It is this aspect of selection bias that makes it danger-
ous: the fact that there is no other option for the source of
study material does not mean that the sample is not biased.
Selection of Controls
Another type of selection bias can arise in determining
who is eligible as a control in a case-control study.16–18
Ideally, the only difference between a case and control should
be the factor under study (exposure, disease, treatment, etc).
In practice, it is nearly impossible to find such controls in
observational settings. An example from the use of serum
peptides to detect prostate cancer might illuminate the diffi-
culties.19 Cases were 25 men with biopsy-verified prostate
cancer, and controls were men who are thought to be free of
prostate cancer because either they were younger than 40
years or had undetectable prostate specific antigen (PSA)
levels in their blood. On the one hand, the level of evidence
required to be a control is much weaker than that of a case.
On the other hand, it is impossible to mandate biopsies on the
controls to rule out occult malignancies. The authors supple-
mented the controls by including young men who are very
unlikely to have prostate cancer, but by doing so, they
introduced another factor that is different between the two
groups: age. To attribute the differences between the serum
peptide characteristics of the cases and controls now requires
either the knowledge or the assumption that age is unrelated
to serum peptide measurements.
This example also points out how frustrating it can be
to try to select controls without bias. This is one reason why
most studies prefer to perform some sort of matching. Al-
though this does not guarantee removal of all bias, it certainly
makes an attempt to decrease it.
Double Dipping
A more scientific name for this kind of bias could be
overfitting, but double dipping summarizes the source of
the bias so clearly that it is preferable in an expository article.
Double dipping refers to the bias created by using the same
dataset for multiple, related analyses. Although there are
many ways one can double dip, one is especially relevant for
prognostic factor studies happens when continuous variables
are categorized by thresholds selected from the same dataset.
It is difficult to find details of published examples of
this type of bias; hence, an unpublished example will be used
in this study. Although the data and the scenario are real, the
analyses shown in this study were carried out only for the
purposes of demonstration in this article. The clinical ques-
tion posed is whether a change in uptake from baseline to
midcycle positron emission tomography scans is prognostic
for pathological response in the setting of neoadjuvant
therapy. The clinical utility of such a prognostic factor is
clear: a patient predicted to have poor pathological re-
sponse at the end of the neoadjuvant treatment may switch
treatments or proceed to surgery early, sparing valuable
time and side effects.
The investigators collected data as a part of an ongoing
clinical trial and reported their findings as seen in Tables 1
and 2. Most of the patients with a large decrease in SUV
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responded and vice versa. In fact, there was only a single
patient with a decrease in SUV more than 35% who never-
theless ended with a response of less than 60%. Summary
statistics reported in Table 2 are very encouraging: SUV is
100% sensitive and 90% specific for pathological response.
In addition, the negative predictive value is estimated to be
100%, that is, if a patient’s SUV does not decrease, there is
a virtual guarantee of lack of response.
Most readers of Tables 1 and 2 object to these conclu-
sions by pointing to the small sample size and the width of the
subsequent (unreported) confidence intervals. This is cer-
tainly a concern. But even with a large sample size, there are
other reasons to object to this style of thinking. Consider the
underlying (noncategorized) data given in Figure 1. Ignoring
the dotted lines for a moment, there is some correlation
between percent decrease in SUV and treatment response.
The upper left corner of the plot is mostly blank, and in very
general terms, a higher decrease in SUV seems to correspond
to a higher treatment response. The correlation between
decrease in SUV and treatment response is 0.50, a respectable
number by most standards. Fitting a line to this set of data
reveals that a stable SUV (no change from baseline) corre-
sponds to a predicted response of 26%, and each additional
10% decrease in SUV translates to an estimated increase of
6% in treatment response. There is a reason to think that a
midcycle positron emission tomography scan contains some
predictive value for the ultimate treatment response.
Nevertheless, the analysis in Table 2 is an overstate-
ment of the evidence provided by the data. The thresholds,
plotted with the dotted lines in Figure 1, reveal that they are
selected to minimize the number of misclassified patients.
This would be the obvious way to select thresholds, yet
Figure 1 makes clear how sensitive the numbers in Table 2
are to the selected thresholds. These thresholds are very
unlikely to survive an evaluation on an independent dataset
and so are the estimates of sensitivity, specificity, and posi-
tive and negative predictive value. Even a minor change in
the thresholds, as shown in Table 3, has a substantial effect on
the reported parameters (and could significantly alter the
study conclusions). Yet, reporting numbers such as the ones
in Tables 1 and 2 instead of Figure 1 and associated analyses
of correlation, intercept, and slope pave the way to strong
conclusions about the prognostic value of SUV. This is partly
not only the result of a small dataset but also the consequence
of double and triple dipping and therefore being overly
optimistic.
Double dipping can happen in other ways too. If one is
fitting a model with many variables with the idea of coming
up with a prognostic score, the resulting model usually is too
much tuned to the data at hand (the term overfit is usually
reserved for this situation). Evaluating the predictive proper-
ties of a model on the same dataset that it is derived from is
sure to lead to optimistic conclusions.20 Statistical methods
have been devised to decrease these optimistic conclu-
sions,21,22 but they have not been in wide-spread use and are
definitely not routinely expected by journal editors and ref-
erees. Even the best of these methods is unlikely to remove
all the optimism because of overfitting, and the ultimate
arbiter should be validation in an independent dataset.
Statistical Analysis in Presence of Bias
It is very important to make this point repeatedly: it is
very difficult, if not outright impossible, to remove bias by
clever statistical analysis. At best, bias can be reduced with
statistical modeling at the cost of making additional assump-
tions, which could, at times, be unverifiable from the ob-
served data. Some of these are discussed in various guidelines
for biomarker studies23 and influential textbooks.24
As an example, consider the hypothetical example of
NPF and suppose that at the time of the original retrospective
study, the investigators suspected that they are dealing with a
sample biased by tumor size. Instead of simply associating
FIGURE 1. Individual data points of changes in SUV after
neoadjuvant therapy and pathologic response.
TABLE 1. Correlation of a Decrease in SUV after
Neoadjuvant Therapy with Pathologic Response
Response
>60%
Response
>60% Total
Decrease in SUV 35% 3 1 4
Decrease in SUV 35% 0 9 9
Total 3 10 13
SUV, standardized uptake value.
TABLE 2. Outcome Parameters for a Decrease in SUV of
35% in Predicting Pathological Response to Neoadjuvant
Therapy
Sensitivity Specificity
Positive
Predictive Value
Negative
Predictive Value
100% 90% 75% 100%
SUV, standardized uptake value.
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NPF with outcome in what is commonly called a univariate
analysis, they have the option of including size and NPF in a
multivariable analysis. This allows them to claim “size-
adjusted” results and possibly draw stronger conclusions.
Few such analyses draw attention to the required assumptions
for such a model. First and foremost, one has to choose an
appropriate multivariable regression model. Although Cox
model has become standard in oncology mostly because of
the modest set of assumptions it requires, it still forces the
proportional hazards (PH) assumption to hold. PH can be
thought of as the condition that the magnitude of the corre-
lation between a factor and outcome (often represented as a
hazard ratio) does not change over time. In my experience,
most clinical investigators have difficulty grasping the mean-
ing of this assumption, and most data analysts, perhaps for
lack of a widely accepted alternative method, tend to accept
the assumption without critical review.
In addition to proportional hazards, there is the func-
tional form of the model to consider. Size, by virtue of being
a continuous variable, can be used as is in a model, that is, as
a continuous covariate. Although it is standard to assume a
linear effect for size, which implies that the incremental
effect of 1 Unit (say centimeter) increase in size is the same
regardless of what the base size is, it is more realistic to think
that the actual effect is more S shaped than a line with a
relatively flat profile for very small or very large tumors.
Most studies, without acknowledging the consequences, ac-
cept the linear form with the (perhaps optimistic) thought that
the middle part of the S is what counts and that it can be
approximated by a line. If, however, the concern was that the
study originally included tumors that were bigger than what
would be expected from a random sample, then the part of the
curve that is most influential in an adjusted analysis would be
the flat portion on the left (i.e., the part that corresponds to
small tumors). In anticipation of this critique, some investi-
gators choose to categorize size. Another argument in favor
of categorization is that it makes it easier to interpret and
communicate the results. The devil, as demonstrated in the
previous section, is in the details: choosing a cutoff point(s)
for a threshold and then carrying out the analysis from the
same dataset will result in overfitting (double dipping).
DISCUSSION
In this article, I have outlined some of the most com-
mon sources of bias in prognostic factor studies and their
potential effects on the conclusions. This is not the first time
these biases are identified or discussed in detail. There are
numerous articles that serve the same purpose. However, the
continued presence of these biases in many published works
and the failure to discuss the implications of these issues
point out to the difficulty of reaching the clinical investigators
who carry out these studies.
These biases, strictly speaking, are not purely statistical
issues. Yet, they are identified with statistics, partly because
statisticians tend to identify them more often and try to
represent or perhaps correct them by modeling their sources.
In my opinion, dealing with biases post hoc is inefficient,
insufficient, and frustrating. It is better to be thoughtful at the
design stage and bring into the discussion various members of
the team including statisticians, pathologists, radiologists, etc.
This will likely delay the data collection but will speed up the
analysis and interpretation of the results, not to mention the
credibility of the conclusions.
The responsibility to notice bias should not be shoul-
dered only by the investigators themselves. Editors, referees,
and readers should demand high-quality reports in this field
that follow the principles of good clinical science. One simple
point (low-hanging fruit) in this respect is the timing of when
a factor is crowned with the adjective “prognostic.” Figure 2
shows the typical stages of development for a prognostic
factor. Current practice is to label the factor as prognostic at
point A, right after the clinical development and certainly
before validation. Some of these prognostic factors are never
validated, some fail validation but their titles are not revoked,
and some are validated only half heartedly. It is our collective
responsibility to demand careful validation before we call
something prognostic and even think about using it in clinical
practice. Indeed, the factors called prognostic only after
reaching point B are much more likely to make a difference
FIGURE 2. Phases in the identification and evaluation of a
robust clinically applicable prognostic factor.
TABLE 3. Effect of Changes in Thresholds on Outcome Parameters
Threshold Sensitivity Specificity Positive Predictive Value Negative Predictive Value
SUV 35%; response 60% 100% 90% 75% 100%
SUV 30%; response 60% 75% 78% 60% 87%
SUV, standardized uptake value.
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clinically. Of course the number of factors reaching point B
will be much smaller than those reaching A. But this by itself
is desirable—we have nothing to lose but our unvalidated
false-prognostic factors.
CONCLUSION
There is a great interest in being able to accurately
predict the future, and a general sense that the key to this is
identification of enough prognostic factors. However, there
are many biases inherent in much of the data we have to work
with, and there are issues buried in the details of how
analyses are done that may result in overly optimistic results.
The great pressure to identify prognostic factors and the
complexity of the details in appropriately evaluating these is
a dangerous combination. This article counters some of the
lack of understanding by pointing out many of the more
common pitfalls, so that investigators and readers can avoid
being led astray. We must be careful in our studies, critical in
our evaluation, and have the patience to seek validation in our
quest to accurately predict outcomes.
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